FDA grants Xtandi priority review for Nonmetastatic CRPC

This article was originally published here

The US Food and Drug Administration (FDA) has accepted Pfizer and Astellas Pharma’s supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) for a new indication and granted priority review designation.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply